September 02, 2014 2:05 PM ET

Pharmaceuticals

Company Overview of Iroko Pharmaceuticals Inc.

Company Overview

Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...

One Kew Place

150 Rouse Boulevard

Philadelphia, PA 19112

United States

Founded in 2012

71 Employees

Phone:

267-546-3003

Fax:

267-546-3004

Key Executives for Iroko Pharmaceuticals Inc.

Chief Executive Officer and President
Executive Chairman of the Board
Age: 52
Chief Financial Officer and Principal Accounting Officer
Age: 67
Senior Vice President
Age: 47
Senior Vice President and Chief Medical Officer
Age: 58
Compensation as of Fiscal Year 2014.

Iroko Pharmaceuticals Inc. Key Developments

Iroko Pharmaceuticals Signs License Agreement with CALOX DE COSTA RICA S.A

Iroko Pharmaceuticals Inc. has signed a licensing agreement with CALOX DE COSTA RICA S.A. for the exclusive rights to market and sell Iroko's ZORVOLEX (diclofenac) capsules in specified countries in Latin America. Both the partners are pharmaceutical companies based in the US and Costa Rica respectively. CALOX will be responsible for obtaining regulatory and pricing approval, as well as the marketing and supply of the medication, in countries including Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Nicaragua, Honduras, Panama and Venezuela. ZORVOLEX was approved by the US Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is now available by prescription. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the US.

Iroko Pharmaceuticals Announces New Strategic Agreement to Commercialize ZORVOLEX(R) in Brazil

Iroko Pharmaceuticals, LLC announced that its affiliate, Iroko Pharmaceuticals Inc., has signed a licensing agreement with EMS around the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Brazil. EMS will be responsible for obtaining regulatory and pricing approval, as well as the marketing and supply of the medication, in that territory. ZORVOLEX was approved by the United States Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is now available by prescription. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the United States. In late 2013, Iroko entered into strategic agreements with Algorithm SAL and PT Pratapa Nirmala (Fahrenheit), under which the two companies obtained the exclusive rights to market and sell ZORVOLEX in countries in the Middle East, North Africa (MENA) and Indonesia, respectively.

Iroko Pharmaceuticals Reports 1st Regulatory Submission Outside U.S. for ZORVOLEX

Iroko Pharmaceuticals reported its affiliate's first regulatory submission outside of the United States for ZORVOLEX (diclofenac) capsules. The new drug application was filed for the nonsteroidal anti-inflammatory drug (NSAID) with the Republic of Lebanon Ministry of Public Health (MOPH). ZORVOLEX was approved by the U.S. Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is not currently approved for marketing in any other country. A supplemental New Drug Application seeking approval for osteoarthritis pain is currently being reviewed by FDA. This filing was the result of a licensing agreement signed late last year by the company's affiliate, Iroko Pharmaceuticals Inc., and Algorithm S.A.L. under which Algorithm obtained the exclusive rights to market and sell ZORVOLEX to countries in the Middle East and North Africa (MENA).

Similar Private Companies By Industry

Company Name Region
D.P. Marketing, Inc. United States
RiboCor, Inc. United States
AtheroMed, Inc. United States
Hercon Laboratories Corporation United States
Anexon, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iroko Pharmaceuticals Inc., please visit www.iroko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.